Abstract:What is known and ObjectiveAlthough ticagrelor has been well‐known to improve clinical outcomes in patients undergoing percutaneous coronary intervention (PCI), and its effectiveness and safety have not been well evaluated in Chinese patients. This study aimed to evaluate the effectiveness and safety of ticagrelor in Chinese patients. In order to find potential effect modifiers on the drug effects, a decision tree method was performed to detect interactions between treatment and patient characteristics in an automatic and systematic manner. MethodsThis retrospective study included acute coronary syndrome (ACS) patients who underwent PCI and received either ticagrelor (N = 250) or clopidogrel (N = 291) while hospitalized between August 2014 and August 2015. After propensity score matching, Kaplan‐Meier analysis was used to study the event‐free survival against major adverse cardiovascular events (MACE, primary efficacy outcome, defined as the composite of cardiac death, non‐fatal myocardial infarction [MI], stroke, restenosis and target vessel revascularization [TVR]), re‐hospitalization, the need for urgent re‐PCI (secondary efficacy outcome) and bleeding events (safety outcome) within 12 months of the PCI date. To search for effect modifiers of the two antiplatelet therapies, a machine‐learning decision tree algorithm was conducted to predict re‐hospitalization status. ResultsAfter propensity score matching (N = 442), ticagrelor and clopidogrel had no significant difference in MACE, re‐hospitalization and bleeding. The decision tree analysis showed that the number of diseased vessels modulated the effect of ticagrelor and clopidogrel on re‐hospitalization rates. In single‐vessel disease (SVD) patients, ticagrelor was associated with lower hazards than clopidogrel for all efficacy outcomes: MACE (HR = 0.190, 95% CI: 0.042–0.866), re‐hospitalization (HR = 0.296, 95% CI: 0.108–0.808), urgent re‐PCI (HR = 0.249, 95% CI: 0.069–0.895), bleeding (HR = 1.006, 95% CI: 0.063–16.129). However, in multi‐vessel disease (MVD) patients, the two treatments did not show significant difference. What is New and ConclusionIn the general patient population, there was no significant difference between ticagrelor and clopidogrel on the hazard of MACE. However, ticagrelor achieved a better effectiveness than clopidogrel in patients with SVD. This pilot study provides scientific basis to call for a large‐scale prospective study in this population.

GW26-e0691 Variability of Ticagrelor Antiplatelet Responsiveness in Chinese ACS Patients

Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention.

Pharmacokinetics and Tolerability of Single and Multiple Doses of Ticagrelor in Healthy Chinese Subjects

Ticagrelor Versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome: A Pharmacodynamic Analysis.

Clopidogrel versus ticagrelor in the treatment of Chinese patients undergoing percutaneous coronary intervention: effects on platelet function assessed by platelet function tests and mean platelet volume

Pharmacodynamics, Pharmacokinetics, and Safety of Ticagrelor in Chinese Patients with Stable Coronary Artery Disease.

Effects of ticagrelor monotherapy vs. clopidogrel monotherapy on platelet reactivity: a randomized, crossover clinical study (SINGLE study)

Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS.

Ticagrelor Pharmacokinetics and Pharmacodynamics in Chinese Patients with STEMI and NSTEMI Without Opioid Administration.

The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population

Analysis of clinical application of ticagrelor, a new oral antiplatelet drug

Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machine‐learning decision tree approaches

A systematic study to evaluate the safety of ticagrelor combined with aspirin in the treatment of PCI patients in Chinese population: A single nucleotide polymorphisms study

Effect of Genetic Polymorphism Including NUP153 and SVEP1 on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects

Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy

Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Ticagrelor Enhances Adenosine-Mediated Antiplatelet Effect In Acute Coronary Syndrome Patients-A Prospective Cohort Study

CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome

Chinese Experts Recommendation on the Monitoring and Management of Variability in Responsiveness to Antiplatelet Therapy

Assessment of ADRB1 polymorphism in patients with acute coronary syndrome treated with ticagrelor and aspirin

Effect of ticagrelor versus clopidogrel on platelet reactivity measured by thrombelastography in patients with minor stroke or TIA